Medicinal plants have been used since ancient times for human healthcare in the form of traditional medicines, spices, and other food components. Throughout history, many different cultures have recognized the potential use of garlic for the prevention and treatment of different diseases. Garlic is a common bulb vegetable or spice that is used as an herb and to flavor food. The plant contains biologically active components that contribute to its pharmacological properties. The medicinal effects of garlic were known for 5,000 years. Garlic is recommended as a nutritive element in the treatment of various health problems and the prolongation of human life. The chemical constituents of garlic have also been investigated for the treatment of aging, Alzheimer’s disease, anti-fungal/bacterial/viral/ Protozoans, atherosclerosis, blood pressure, cancer, cardiovascular disease, diabetes, neuro/ nephroprotection, osteoporosis, stress, hyperlipidemia, and, wound healing and highly praised by several authors. Therefore, this paper is reviewed to inspire and impress young researchers about the medicinal values of garlic.
Stem cells are undifferentiated cells that can proliferate, regenerate, develop into differentiated cells, and produce a variety of tissues. Embryonic stem cells, adult or somatic stem cells, and pluripotent stem cells are the three types of stem cells. Another classification of stem cells is totipotent, multipotent, and unipotent cells. Stem cell treatment has the possibility of treating degenerative disorders, cancer, and the restoration of damaged tissues, all of which now have no or restricted medicinal alternatives. Myocardial infarction is a potentially fatal condition caused by the permanent loss of cardiomyocytes and a deterioration in the heart's blood-pumping capacity. Throughout the last two decades, stem cell-based treatments for myocardial infarction therapy have been researched with encouraging results. Traditional therapy for myocardial infarction slows disease development but has little effect on healing. Because of their ability to initiate de novo cardiogenesis, embryonic stem cells are thought to be a potential candidate for cardiac regeneration.
This extensive review delves into the complex relationship between prolonged use of metformin and the possible emergence of vitamin B12 deficiency (VB12D) in diabetic patients. Metformin, a pivotal element in diabetes management, is constantly linked with decreased absorption of vitamin B12, prompting concerns about the enduring consequences of this interaction. The review systematically amalgamates current evidence, elucidating the prevalence, mechanisms, and clinical ramifications of VB12D induced by consistent consumption of metformin. Exploring the different pathways through which metformin might disrupt the absorption of Vitamin B12, the review encompasses interference with the calcium-dependent membrane activity and alterations of the microbiota present in the gut. A meticulous analysis of experimental studies and human trials is undertaken, accentuating the prevalence of variable VB12D among individuals on long-duration treatment of metformin across diverse populations and age groups. Clinical indications of cobalamin deficiency, spanning haematological abnormalities to neurological complications, are systematically examined. Furthermore, the review delves into the potential implications of cobalamin deficiency associated with metformin on diabetes-related complications and overall patient health. This review offers a comprehensive overview of the intricate interplay between the use of metformin and deficiency of vitamin B12 in diabetic patients, emphasizing the importance that lies in routine monitoring, early detection, and personalized interventions to optimize the long-period safety and efficiency of metformin in the treatment of diabetes. It also proposes future research directions to refine clinical guidelines and enhance the understanding regarding the correlation between diabetes, metformin, and vitamin B12.
Depression is a prevalent mood disorder with significant public health implications. Despite extensive research, its precise causes remain inadequately understood. Recently, interest has surged in the role of the gut microbiome and its metabolites in the pathophysiology of depression. This review aims to provide a comprehensive overview of the relationship between gut microbiota, its metabolites, and depression while exploring potential mechanisms influencing the efficacy of antidepressant medications. A narrative review methodology was employed, synthesizing recent studies utilizing a multi-omics approach. We examined alterations in gut microbiome composition and metabolite production in individuals diagnosed with depression, discussing the technical tools and methods commonly applied in this research area. The findings indicate that individuals with depression show significant alterations in gut microbiome composition, notably an imbalance in Firmicutes, Bacteroidetes, and Actinobacteria. Changes in metabolite production, including short-chain fatty acids, tryptophan, and bile acids, were also observed. Moreover, the review highlights that antidepressant medications may exert their therapeutic effects by modulating gut microbiota and its metabolites. This review emphasizes the intricate interplay between gut microbiota, its metabolites, and depression, revealing critical insights into the mechanisms underlying antidepressant efficacy. We recommend that future research focus on elucidating these interactions to develop innovative therapeutic strategies, potentially transforming the management of depression through microbiota-targeted approaches.
Lifestyle has historically been linked to the progression of different chronic diseases. The amount of convenience accessible for our use has expanded in the current period of modern technology, communication, and technological devices. Nevertheless, it has also resulted in an upsurge in issues related to emotional and mental wellness. Asthma, coronary heart disease (CHD), diabetes, lung cancer, and other disorders are all classified as lifestyle diseases. This theory contends that illnesses are brought on by an individual’s actions. The transition from an indigenous to a contemporary way of life, with high-fat and high-calorie meals paired with increasing emotional strain, has exacerbated the issue at hand. Obesity, asthma, diabetes, arthritis, hypertension, chronic liver disorders, CHD, metabolic syndrome, depression, and cancer are all on the rise due to alterations to dietary habits and an increasingly unhealthy way of life. According to joint research by the World Health Organization (WHO) and the World Economic Forum (WEF), India lost around $236.6 billion in 2015 as a result of a sedentary way of life and consumption of unhealthy foods. Unhealthy eating, decreased physical activity, increased cigarette smoking, excessive alcohol consumption, insufficient sleep, and anxiety due to increasing job pressure are all examples of poor lifestyle choices.
Haemovigilance is considered to be the collection of monitoring measures that encompass the entire transfusions process ranging from monitoring of blood to the prevention of blood-related disease. The term hemovigilance originated from the word pharmacovigilance, which comprises operations and methods to gather intelligence valuable in overseeing pharmaceutical goods, particularly adverse drug responses in humans, and to scientifically assess such data. This follows the reporting system which includes the enhancement of patient safety. It also includes learning from failures that result in certain system changes and thus prevents the associated errors. It also includes all key parties and organizes numerous operations among blood banks, transfusion facilities, and hospital caregivers. The majority of affluent nations now use Haemovigilance to track adverse responses and occurrences connected with blood donation and transfusion. This mini-review sheds the light on an overview of haemovigilance from an Indian perspective